In the BioHarmony Drug Report Database

"Preview" Icon

Tucatinib

Tukysa (tucatinib) is a small molecule pharmaceutical. Tucatinib was first approved as Tukysa on 2020-04-17. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms and neoplasm metastasis. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2 and receptor tyrosine-protein kinase erbB-3. In addition, it is known to target epidermal growth factor receptor and receptor tyrosine-protein kinase erbB-4. Tukysa’s patents are valid until 2032-10-12 (FDA).

 

Trade Name

 

Tukysa
 

Common Name

 

tucatinib
 

ChEMBL ID

 

CHEMBL3989868
 

Indication

 

breast neoplasms, neoplasm metastasis
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Tucatinib structure rendering